

0300

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage First Class Mail in an envelope addressed to Box Sequence, P.O. Bx 2327, Commissioner for Patents, Arlington, VA 22202 on the date shown below.

Date: May 24, 2002

By: Carol A. See
Carol A. See

PATENT
Docket No. GC652

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
Andrew Shaw)	Group Art Unit: 1645
)	
Serial No.: 10/068,374)	Examiner: Unassigned
)	
Filed: February 6, 2002)	
)	
For: Modified Target Enzymes Having)	
Catalytic Triads and Uses Thereof)	

TRANSMITTAL LETTER FOR NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES

Box Sequence
Commissioner for Patents
Arlington, VA 22202

Sir:

In complete response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated March 28, 2002, enclosed please find:


- ☐ a Combined Declaration and Power of Attorney signed by the inventor(s) and the surcharge of \$130.00 as set forth in 37 C.F.R. § 1.16(e);
- ☐ Petition for a _____ Month Extension of Time;
- ☐ Assignment document, Form PTO-1595, and the \$40.00 Assignment Recording Fee;
- ☒ Associate Power of Attorney;
- ☒ Preliminary Amendment
- ☒ Statement of Sameness

- ☒ [X] Paper copy of Sequence Listing (4 pages)
- ☒ [X] Diskette copy of Sequence Listing
- ☐ [] Request for Use of an Identical Computer Readable Form in Another Application Under 37 CFR § 1.821(e);
- ☒ [X] Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (copy of Notice to be returned with response);
- ☐ [] Form PTO-1533 (copy of Notice to be returned with response); and
- ☐ [] Other: _____
- ☐ [] Charge \$_____ to Deposit Account No. 07-1048.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC652). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: May 24, 2002


Kamrin T. MacKnight
Registration No. 38,230

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-5838
Fax: 650-845-6504



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/068,374	02/06/2002	Andrew Shaw	GC652

H. THOMAS ANDERTON
GENENCOR INTERNATIONAL, INC.
925 PAGE MILL ROAD
PALO ALTO, CA 94304



CONFIRMATION NO. 6144

FORMALITIES LETTER



OC000000007737954

Date Mailed: 03/28/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE